Nabriva Therapeutics plc (NBRVF)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Apr 15, 2026
-99.00%
Market Cap 3.00
Revenue (ttm) 29.56M
Net Income (ttm) -55.05M
Shares Out 3.23M
EPS (ttm) -17.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 520
Average Volume 1,149
Open 0.0000
Previous Close 0.0000
Day's Range 0.0000 - 0.0000
52-Week Range 0.0000 - 0.0002
Beta 5.32
RSI 36.04
Earnings Date n/a

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); XENLETA for the treatment of community-acquired bacterial pneumonia; and CONTEPO for the treatment of complicated urinary tract infections, including acute pyelonephritis. The company was formerly known as Nabriva Therapeutics ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 39
Stock Exchange OTCMKTS
Ticker Symbol NBRVF
Full Company Profile

Financial Performance

In 2022, Nabriva Therapeutics's revenue was $36.94 million, an increase of 27.82% compared to the previous year's $28.90 million. Losses were -$57.19 million, 15.6% more than in 2021.

News

There is no news available yet.